Corrigendum to “Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine” [Vaccine 28 (2010) 8065–8072]

Incidence in Gardasil group (per 100 person-years) Incidence in placebo group (per 100 person-years) Risk difference (placebo-Gardasil) (95% CI) Number of cases prevented annually per 100,000 vaccinated women (95% CI) HPV-naïve population (n=9296)b Any CIN (CIN 1-3 or AIS) 1.68 2.39 0.71 (0.40-1.02) 710 (400-1020) CIN 3 or AIS 0.22 0.39 0.17 (0.05-0.28) 170 (50-280) Any Pap smear abnormalities 6.65 8.03 1.38 (0.76-1.99) 1380 (760-1990) Definitive cervical therapy 0.79 1.37 0.58 (0.36-0.80) 580 (360-800) HPV-exposed and -unexposed (ITT) population (n=17,160)c Any CIN (CIN 1-3 or AIS) 3.39 4.19 0.80 (0.48-1.12) 800 (480-1120) CIN 3 or AIS 0.81 0.98 0.18 (0.03-0.33) 180 (30-330) Any Pap smear abnormalities 10.36 11.68 1.32 (0.74-1.90) 1320 (740-1900) Definitive cervical therapy 1.97 2.56 0.59 (0.35-0.83) 590 (350-830) Table 3 Efficacy of Gardasil in preventing CIN or AIS in women enrolled in the FUTURE I and II trials and followed up for a mean of 3.6 years (maximum 4.9 years) [42]a. AIS: adenocarcinoma in situ; CI: confidence interval; CIN: cervical intraepithelial neoplasia; Pap: Papanicolaou.